ABSTRACT
INTRODUCTION: It is important to know the reasons for resubmitting research projects to the Research Ethics Committee in order to help researchers to prepare their research projects, informed consent forms and needed research documentation. OBJECTIVES: To verify the reasons for resubmitting projects that were previously rejected by the Ethics Committee. METHOD: This is a cross-sectional study that evaluated research projects involving human beings. Research projects were submitted in 2007 to the Research Ethics Committee of the Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo. RESULTS: One thousand two hundred and fifty six research projects were submitted to the ethics committee and the average time for evaluating the research projects and related documents until a final decision was reached was 49.95 days. From the total, 399 projects were reviewed in 2 or more meetings until a final decision was reached. Of these, 392 research projects were included in the study; 35 projects were subsequently excluded for involving animals. Among the research projects included, 42.5 percent concerned research with new drugs, vaccines and diagnostic tests, 48.5 percent consisted of undergraduate students' research projects, 68.9 percent of the research had no sponsorship, and 97.5 percent were eventually approved. The main reasons for returning the projects to the researchers were the use of inadequate language and/or difficulty of understanding the informed consent form (32.2 percent), lack of information about the protocol at the informed consent form (25.8 percent), as well as doubts regarding methodological and statistical issues of the protocol (77.1 percent). Other reasons for returning the research projects involved lack of, inaccuracy on or incomplete documentation, need of clarification or approval for participation of external entities on the research, lack of information on financial support. CONCLUSION: Among the ...
Subject(s)
Animals , Humans , Biomedical Research/standards , Consent Forms/standards , Ethics Committees, Research/statistics & numerical data , Research Design/standards , Brazil , Biomedical Research , Biomedical Research/statistics & numerical data , Cross-Sectional Studies , Consent Forms , Consent Forms/statistics & numerical data , Hospitals, University , Research Design/statistics & numerical dataABSTRACT
O presente trabalho porcura avaliar o padräo hipnótico de nova substância, uma ciclopirrolona (Zopiclone), comparando-a com droga já estabelecida (Midazolam). Realizou-se estudo duplo-cego, com 90 pacientes, em grupos paralelos, com dose fixa de Zopiclone (7,5mg) ou Midazolam (15mg). Os pacientes foram acompanhados com escalas de auto e heteroavaliaçäo por três semanas. Ambas as drogas foram significantemente eficazes em todas as medidas de avaliaçäo. O grupo que utilizou Zopiclone apresentou resposta clínica significantemente mais acentuada que o grupo em uso de Midazolam. O Zipiclone apresentou número menor de pacientes com efeito colaterais. A gravidade e o número de efeitos foram semelhantes com melhor vantagem para o grupo Zopiclone. Ambas as drogas säo eficazes e seguras para o tratamento sintomático e breve de insônia crônica, porém o perfil fármaco-clínico do Zopiclone aproxima-o mais do hipnótico ideal
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Anti-Anxiety Agents/therapeutic use , Double-Blind Method , Sleep Initiation and Maintenance Disorders/drug therapy , Midazolam/therapeutic use , Sleep/drug effects , Anti-Anxiety Agents/pharmacology , Midazolam/pharmacologyABSTRACT
O presente trabalho procura avaliar o padräo hipnótico de nova substância, uma ciclopirrolona (Zopiclone), comparando-a com droga já estabelecida (Midazolam). Realizou-se estudo duplo-cego, com 90 pacientes, em grupos paralelos, com dose fixa de Zopiclone (7,5mg) ou Midazolam (15mg). Os pacientes foram acompanhados com escalas de auto e heteroavaliaçäo por três semanas. Ambas as drogas foram significativamente eficazes em todas as medidas de avaliaçäo. O grupo que utilizou Zopiclone apresentou resposta clínica significativamente mais acentuada que o grupo em uso de Midazolam. O Zopiclone apresentou número menor de pacientes com efeitos colaterais. A gravidade e o número de efeitos colaterais foram semelhantes com mais vantagem para o grupo Zopiclone. Ambas as drogas säo eficazes e seguras para o tratamento sintomático e breve de insônia crônica, porém o perfil fármaco-clínico do Zopiclone aproxima-o mais do hipnótico ideal